Sabine Pinnetti
Biberach An Der Riss, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Clinical trial simulations in pulmonary fibrosis: patient-focused insights and adaptations.
Journal: ERJ open research
Published: November 08, 2022
Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers.
Journal: Clinical therapeutics
Published: February 26, 2015
Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus.
Journal: Current medical research and opinion
Published: January 29, 2015
Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus.
Journal: Clinical therapeutics
Published: October 08, 2014
Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers.
Journal: International journal of clinical pharmacology and therapeutics
Published: August 28, 2014
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.
Journal: Diabetes care
Published: November 05, 2013
Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study.
Journal: Diabetes care
Published: September 25, 2013
Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: May 07, 2013
Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Journal: Diabetes, obesity & metabolism
Published: April 08, 2013
Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.
Journal: Clinical drug investigation
Published: March 21, 2013
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
Journal: Diabetes, obesity & metabolism
Published: March 13, 2013
Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.
Journal: Diabetes, obesity & metabolism
Published: January 21, 2013
Last Updated: 09/26/2026